Clinical trialsCompany release

Benitec: all treated OPMD patients responded to BB-301; pivotal trial planned for mid-2027

🇺🇸 Benitec Biopharma Inc. (BNTC) · Fri 13 Nov 2026

Interim Phase 1b/2a data in oculopharyngeal muscular dystrophy dysphagia showed responses in every Cohort 1 and 2 patient, with no serious adverse events, alongside Benitec's fiscal first-quarter results.

Benitec Biopharma reported results for its fiscal first quarter of 2027, the quarter ended 30 September 2026, on 13 November 2026. The company used the update to highlight progress with BB-301 in dysphagia linked to oculopharyngeal muscular dystrophy (OPMD).

Interim Phase 1b/2a data, presented at the ESGCT meeting on 28 October 2026, showed that all patients in Cohorts 1 and 2 responded to treatment. Benitec said no serious adverse events had been reported. The summary available does not give patient numbers, response definitions or follow-up duration, so the strength of the 100% responder figure cannot be assessed from it.

Benitec expects to finalise the design of its pivotal trial in the first quarter of 2027 and to start the study in mid-2027. The company reported cash of about $176.5 million.

Benitec also plans to move its fiscal year-end from 30 June to 31 December. Such a change typically shifts the reporting calendar, so analysts and partners tracking the company will need to adjust their comparisons between periods.

What it means for your team

  • Regulatory teams following gene-therapy programmes in rare disease should watch for the finalised pivotal design in Q1 2027, including the choice of endpoints and trial population.
  • Pharmacovigilance and safety reviewers should note that the absence of serious adverse events is an interim, early-phase finding; the available details do not include sample size or follow-up length.
  • Market-access and HTA planners can treat mid-2027 as the expected pivotal start, which sets the earliest horizon for any pivotal evidence on OPMD dysphagia.
  • Anyone tracking company filings should allow for the planned switch to a 31 December year-end.

Company's press release (SEC filing): Benitec Biopharma Inc. ↗

Article written by VigiEye from the official source (Benitec Biopharma Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →